



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,722	12/10/2004	Peter Neu	00143-00244-US	6059
23416	7590	01/09/2006	EXAMINER	
CONNOLLY BOVE LODGE & HUTZ, LLP			ARNOLD, ERNST V	
P O BOX 2207			ART UNIT	
WILMINGTON, DE 19899			PAPER NUMBER	
			1616	

DATE MAILED: 01/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/517,722

Applicant(s)

NEU ET AL.

Examiner

Ernst V. Arnold

Art Unit

1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-11 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-11 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

The Examiner acknowledges receipt of application number 10/517,722 filed on 12/10/2004. Claims 1-11 are pending and are accordingly presented for examination on the merits.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

The claimed invention is directed to non-statutory subject matter. The limitation of instant claim 1 is drawn to xenon gas with an intended use as a medicament for cerebral protection. The Examiner interprets this to read upon xenon gas, which is a natural product.

Claim Rejections - 35 U.S.C. §§ 101 and 112, Second Paragraph

The following are quotations of 35 U.S.C. §§ 101 and 112, second paragraph, respectively, which form the basis of the claim rejections as set forth under this particular section of the Official Action:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 7-11 are rejected under 35 U.S.C. § 101 as being drawn to use claims, which are non-statutory process claims, as defined in 35 U.S.C. § 101. See, *Ex parte Dunki*, 153 USPQ 678 (Bd. App. 1967). In addition, claims 6 and 7 are also rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention. More specifically, a claim is rendered indefinite when said claim merely recites a use without any active, positive steps delimiting how this use is actually practiced. See MPEP 2175.03(q). As a result, the Applicants are respectfully required to redraft the aforementioned use claims as statutory process claims that delimit active, positive steps on how to use a composition according to the invention as originally filed.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 7 and 9-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is unclear to the Examiner the meaning of "where appropriate". What is appropriate versus inappropriate?

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-2 and 9-11 are rejected under 35 U.S.C. 102(b) as being anticipated by Fishman (US 5,228,434).

Instant claim 1 is drawn to a spasmolytic comprising xenon or a xenon-containing gas mixture.

Fishman disclose a mixture consisting of from 60 to 78.5 mole percent stable xenon, from 19.5 to 38 mole percent oxygen and from 2.5 to 20.5 mole percent helium (Claim 1). Methods of making and methods of using the gas mixture are disclosed

Art Unit: 1616

(Column 3, lines 14-42 and column 5, lines 8-36). The gas mixture is provided to the patient in sufficient amount to anesthetize the patient and thus reads on instant claims 1 and 2. The Examiner interprets "where appropriate" to include no source of NO.

With respect to the art rejection above, it is noted that the reference does not teach that the composition can be used in the manner instantly claimed, however, the intended use of the claimed composition does not patentably distinguish the composition, per se, since such undisclosed use is inherent in the reference composition. In order to be limiting, the intended use must create a structural difference between the claimed composition and the prior art composition. In the instant case, the intended use does not create a structural difference, thus the intended use is not limiting.

Claim Rejections - 35 USC § 102

Claims 1, 2, 7, 10 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Petzelt et al. (WO 00/53192).

Petzelt et al. disclose preparations and methods of use of xenon or xenon gas mixtures for treating neurointoxications (a chronic cerebral disorder such as Parkinson's disease) in a therapeutically useful concentration (Page 5, paragraph 1; page 11, paragraph 4 and claims 1, 7 and 16, for example). The preparation can have a ratio of xenon to oxygen of 80 to 20 percent by volume thus reading on instant claims 1-3 (Page 8, second paragraph and claims 15 and 17). Administration is by simple inhalation (Page 12, line 1). Methods of mixing the gases are provided (Page 8, paragraphs 3 and

Art Unit: 1616

4). Methods of administration are also provided (Page 9, paragraphs 1 and 2). The Examiner interprets "where appropriate" to include no source of NO.

With respect to the art rejection above, it is noted that the reference does not teach that the composition can be used in the manner instantly claimed, however, the intended use of the claimed composition does not patentably distinguish the composition, per se, since such undisclosed use is inherent in the reference composition. In order to be limiting, the intended use must create a structural difference between the claimed composition and the prior art composition. In the instant case, the intended use does not create a structural difference, thus the intended use is not limiting.

Claim Rejections - 35 USC § 102

Claims 1-10 are rejected under 35 U.S.C. 102(b) as being anticipated by Briend et al. (WO 97/15311).

Briend et al. disclose nitrogen monoxide (NO) composition for use as a drug (Title). The use of a gaseous composition containing NO and carbon dioxide for preparing a drug useful for the intravascular treatment or prevention of ischaemia is disclosed (Abstract and claim 1). It is the Examiner's position that in order to treat or prevent ischaemia a therapeutically effective amount is present of the gas(es). The gaseous drug additionally comprises at least one gas chosen from the group of nitrogen protoxide, xenon, krypton and their mixtures (Claims 1 and 3). Briend et al. thus disclose the instantly claimed composition comprising xenon and NO.

With respect to the art rejection above, it is noted that the reference does not teach that the composition can be used in the manner instantly claimed, however, the intended use of the claimed composition does not patentably distinguish the composition, per se, since such undisclosed use is inherent in the reference composition. In order to be limiting, the intended use must create a structural difference between the claimed composition and the prior art composition. In the instant case, the intended use does not create a structural difference, thus the intended use is not limiting.

Claim Rejections - 35 USC § 102

Claims 1-10 are rejected under 35 U.S.C. 102(b) as being anticipated by Briend et al. (US 5,670,177).

Briend et al. disclose a gaseous mixture for treatment of prevention of ischemia comprising: nitric oxide in an amount effective to prevent ischemia; carbon dioxide; nitrogen protoxide; and at least one of xenon, krypton, and their mixtures (Claims 1 and 2). It is the Examiner's position that in order to prevent ischaemia a therapeutically effective amount of the gas(es) is present. Briend et al. administer the composition by an intravascular route thus reading on instant claim 4 (Abstract and claims 10-12). Briend et al. thus disclose the instantly claimed composition comprising xenon and NO.

With respect to the art rejection above, it is noted that the reference does not teach that the composition can be used in the manner instantly claimed, however, the intended use of the claimed composition does not patentably distinguish the

Art Unit: 1616

composition, per se, since such undisclosed use is inherent in the reference composition. In order to be limiting, the intended use must create a structural difference between the claimed composition and the prior art composition. In the instant case, the intended use does not create a structural difference, thus the intended use is not limiting.

Double Patenting

1) Claims 1-4, 6, 7 and 9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2 and 4-7 of copending Application No. 10/10/517,723. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims embrace or are embraced by the copending claims. Instant claim 1 and copending claim 1 are drawn to xenon or xenon-containing gas mixtures. Instant claim 2 and copending claim 2 are drawn to therapeutically effective amounts of xenon. Instant claim 4 comprises a spasmolytic and xenon which makes obvious copending claim 4 composition comprising xenon and a NO source. NO is a spasmolytic. Copending claim 5 and instant claims 2 and 3 are drawn to therapeutically effective amounts of NO and xenon. Copending claim 6 and instant claim 7 are drawn to the use of the xenon and where appropriate NO source. Copending claim 7 and instant claim 9 are drawn to the use of xenon and where appropriate an NO source for the therapy or prophylaxis of impairments of cognitive performance.

One of ordinary skill in the art would have recognized the obvious variation of the instant claims in the copending application because of the overlap in claimed subject matter as stated above.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

2) Claim 1 is provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 of copending Application No. 10/518,067. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims embrace or are embraced by the copending claims. Instant claim 1 is drawn to a spasmolytic comprising xenon or a xenon-containing gas mixture and copending claim 1 is drawn to an adjuvant comprising xenon or a xenon-containing gas.

One of ordinary skill in the art would have recognized the obvious variation of the instant claims in the copending application because of the overlap in claimed subject matter as stated above.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

3) Claims 1 and 2 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 22, 24, 25 and 27 of copending Application No. 10/380,869. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims embrace or are embraced by the copending claims. Instant claim 1 is drawn to a

Art Unit: 1616

spasmolytic comprising xenon or a xenon-containing gas mixture and copending claim 1 is drawn to a drug comprising xenon. Copending claim 24 is drawn to xenon as part of a gas mixture and copending claim 25 is drawn to pure xenon. Copending claim 27 is drawn to anesthetically effective amount of xenon and instant claim 2 is drawn to xenon present in a therapeutically effective amount.

One of ordinary skill in the art would have recognized the obvious variation of the instant claims in the copending application because of the overlap in claimed subject matter as stated above.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ernst V. Arnold whose telephone number is 571-272-8509. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

EVA



JOHN PAK
PRIMARY EXAMINER
GROUP 1600